BioStem lands up to $40M equity facility from Roth
What's the deal? BioStem Technologies (Nasdaq: BSEM), a regenerative medicine company, has entered a $40 million committed equity facility with Roth Principal Investments, an affiliate of Roth Capital PartnersDealroom has a profile for this one. Try Dealroom →. The arrangement lets BioStem sell up to $40 million of common stock to Roth at its own discretion via private placement, subject to conditions.
What does BioStem do? The Pompano Beach, Florida company develops, manufactures, and commercialises perinatal tissue allograft products.
Why it matters: A committed equity facility gives BioStem an on-demand funding line without an obligation to draw the full amount. The company said it may "access capital opportunistically over time," using net proceeds for working capital and general corporate purposes.
The fine print: Under Nasdaq rules, BioStem cannot issue Roth more than 19.99% of shares outstanding without shareholder approval or a qualifying average price. The facility hinges on a resale registration statement clearing the US Securities and Exchange Commission — a step that could be delayed or blocked.
The signal: At $40 million, the deal sits in the 92nd percentile of private placement rounds over the trailing 48 months, based on a sample of 5,673 deals. That scale signals meaningful capital access for a small-cap regenerative medicine player, though how much BioStem taps will depend on its stock and market conditions.
Image credit: BioStem Technologies
